바이오테크놀러지 원료 시장 예측(-2032년) : 제품 유형, 공급원, 생산 방법, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Biotech Ingredients Market is accounted for $2.61 billion in 2025 and is expected to reach $5.03 billion by 2032 growing at a CAGR of 9.8% during the forecast period. Biotech ingredients are components produced using advanced biotechnological techniques such as fermentation, enzyme catalysis, or genetic modification. They are utilized across sectors including food, pharma, cosmetics, and agriculture to enhance product performance, nutritional content, and safety. These ingredients allow for the development of functional, bioactive, and environmentally sustainable products by employing cells, microbes, or enzymes, offering an efficient and innovative alternative to conventional chemical-based production methods.

Market Dynamics:

Driver:

Rising demand for functional foods and nutraceuticals

The global surge in health-conscious consumers is propelling demand for biotech-derived ingredients in functional foods and nutraceuticals. These ingredients offer targeted health benefits, such as immune support, digestive wellness, and metabolic balance, driving their inclusion in daily diets. Biotech innovations are enabling precise formulation of ingredients like peptides, enzymes, and probiotics to enhance efficacy. Personalized nutrition trends and preventive healthcare models are accelerating adoption across food and beverage sectors. Regulatory support for health claims and clean-label formulations is also boosting market confidence. As consumers seek natural, science-backed solutions, biotech ingredients are becoming central to next-gen wellness products.

Restraint:

High production and R&D costs

Advanced R&D is required to optimize yield, bioavailability, and safety, often demanding multi-year investments. Scaling up from lab to commercial production introduces technical hurdles and cost inefficiencies. Regulatory compliance, including clinical validation and safety approvals, adds further financial strain. Intellectual property protection and patent filings increase overhead for innovation-driven firms. These challenges deter smaller players and slow down time-to-market for novel ingredients. As a result, many companies adopt phased development strategies or seek partnerships to mitigate financial risks.

Opportunity:

Innovations in enzyme and microbial technology

Tailored enzymes are improving reaction specificity, stability, and scalability in ingredient production. Microbial platforms, including genetically modified strains, are being optimized for high-yield biosynthesis of vitamins, amino acids, and bioactive peptides. These technologies reduce reliance on chemical synthesis and support sustainable manufacturing practices. Integration with AI and bioinformatics is accelerating strain selection and process optimization. Startups and research institutions are collaborating to commercialize novel microbial pathways for niche applications. This wave of innovation is expected to reshape ingredient portfolios and expand market access across food, pharma, and cosmetic sectors.

Threat:

Intense competition from synthetic alternatives

Established chemical manufacturers leverage economies of scale and streamlined supply chains to undercut biotech pricing. In some cases, synthetic versions offer comparable functionality, making it difficult to justify premium biotech options. Regulatory ambiguity around natural vs. synthetic labeling further blurs consumer perception. Marketing claims and brand positioning play a critical role in influencing buyer preferences. Without clear differentiation in efficacy or sustainability, biotech ingredients risk being sidelined. Continuous innovation and transparent communication are essential to defend market share against synthetic substitutes.

Covid-19 Impact:

The COVID-19 pandemic reshaped priorities in biotech ingredient development, emphasizing immunity, hygiene, and resilience. Demand surged for ingredients supporting respiratory health, stress reduction, and antiviral properties. Supply chain disruptions affected raw material availability and delayed production timelines. Companies accelerated digital transformation, adopting remote R&D tools and cloud-based collaboration platforms. However, budget reallocations and operational constraints slowed non-essential innovation pipelines. Post-pandemic strategies now focus on agility, health preparedness, and diversified sourcing to withstand future disruptions.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is expected to account for the largest market share during the forecast period, due to its widespread application in therapeutic and diagnostic products. These biologics offer high specificity and efficacy in targeting disease pathways, making them indispensable in modern medicine. Biotech advancements have improved antibody stability, scalability, and delivery mechanisms. Growing prevalence of autoimmune disorders, cancers, and infectious diseases is driving demand for antibody-based treatments. Pharmaceutical companies are investing heavily in monoclonal antibody pipelines and biosimilar development. Regulatory approvals and reimbursement frameworks are supporting market expansion.

The cosmetic manufacturers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cosmetic manufacturers segment is predicted to witness the highest growth rate, driven by demand for clean, functional, and bioactive formulations. Consumers are increasingly seeking skincare and personal care products with scientifically validated benefits. Biotech ingredients such as peptides, enzymes, and fermented extracts offer anti-aging, hydration, and skin barrier support. Innovations in delivery systems and encapsulation are enhancing ingredient performance and shelf stability. Brands are leveraging biotech to differentiate in a crowded market and meet regulatory standards for safety and efficacy. Social media and influencer marketing are amplifying awareness of biotech-based cosmetics.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, fueled by robust manufacturing ecosystems and rising health awareness. Countries like China, India, Japan, and South Korea are investing in biotech infrastructure and R&D capabilities. Traditional medicine integration and dietary supplement consumption are driving demand for natural and functional ingredients. Government initiatives supporting biotech innovation and export competitiveness are accelerating market growth. Urbanization and rising disposable incomes are expanding consumer access to premium wellness products. Regional players are forming strategic alliances to scale production and distribution.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, propelled by cutting-edge research and strong regulatory frameworks. The U.S. and Canada are home to leading biotech firms and academic institutions driving ingredient innovation. Consumer demand for transparency, sustainability, and efficacy is shaping product development strategies. Venture capital and federal funding are supporting startups focused on novel biosynthesis pathways. The region's emphasis on personalized nutrition and preventive healthcare is boosting biotech ingredient adoption. Strategic collaborations between pharma, food, and cosmetic sectors are fostering cross-industry innovation.

Key players in the market

Some of the key players in Biotech Ingredients Market include Novozymes A/S, DuPont, dsm-firmenich, Novus International, Inc., AB Enzymes GmbH, Evonik Industries AG, BASF SE, Amyris, Inc., Givaudan, Ginkgo Bioworks, Chr. Hansen Holding A/S, Codexis, Inc., Kerry Group plc, Lonza Group, and Corbion N.V.

Key Developments:

In September 2025, DuPont has signed an agreement to acquire Sinochem RO Memtech Co., Ltd. to expand its reverse osmosis (RO) manufacturing footprint into China and the Asia Pacific region. With advanced membrane and fabrication production technologies, the acquisition increases DuPont's capacity to meet the growing demand in the region for FilmTec(TM) elements for industrial water purification and reuse.

In September 2025, dsm-firmenich launches four new Dairy Safe(TM) culture rotations. These all-in-one, label-friendly solutions deliver assured bioprotection through improved phage robustness as well as greater temperature resistance, controlled eye formation, consistent acidification, and enhanced flavor development for premium semi-hard, hard, and continental-style cheese varieties.

Types Covered:

• Active Pharmaceutical Ingredients (APIs)
• Biosimilars
• Nucleic Acids
• Enzymes
• Peptides
• Monoclonal Antibodies
• Polysaccharides
• Other Types

Sources Covered:

• Microbial
• Animal
• Plant
• Algae
• Other Sources

Production Methods Covered:

• Fermentation
• Extraction from Natural Sources
• Recombinant DNA Technology
• Synthetic Biology
• Cell Culture Technology

Applications Covered:

• Pharmaceuticals
• Agriculture & Animal Feed
• Personal Care & Cosmetics
• Industrial Biotechnology
• Food & Beverages
• Nutraceuticals
• Other Applications

End Users Covered:

• Pharmaceutical & Biopharmaceutical Companies
• Contract Manufacturing Organizations (CMOs)
• Cosmetic Manufacturers
• Research Institutes
• Food Processing Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Biotech Ingredients Market, By Type

• 5.1 Introduction
• 5.2 Active Pharmaceutical Ingredients (APIs)
• 5.3 Biosimilars
• 5.4 Nucleic Acids
• 5.5 Enzymes
• 5.6 Peptides
• 5.7 Monoclonal Antibodies
• 5.8 Polysaccharides
• 5.9 Other Types

6 Global Biotech Ingredients Market, By Source

• 6.1 Introduction
• 6.2 Microbial
• 6.3 Animal
• 6.4 Plant
• 6.5 Algae
• 6.6 Other Sources

7 Global Biotech Ingredients Market, By Production Method

• 7.1 Introduction
• 7.2 Fermentation
• 7.3 Extraction from Natural Sources
• 7.4 Recombinant DNA Technology
• 7.5 Synthetic Biology
• 7.6 Cell Culture Technology

8 Global Biotech Ingredients Market, By Application

• 8.1 Introduction
• 8.2 Pharmaceuticals
• 8.3 Agriculture & Animal Feed
• 8.4 Personal Care & Cosmetics
• 8.5 Industrial Biotechnology
• 8.6 Food & Beverages
• 8.7 Nutraceuticals
• 8.8 Other Applications

9 Global Biotech Ingredients Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical & Biopharmaceutical Companies
• 9.3 Contract Manufacturing Organizations (CMOs)
• 9.4 Cosmetic Manufacturers
• 9.5 Research Institutes
• 9.6 Food Processing Companies
• 9.7 Other End Users

10 Global Biotech Ingredients Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Novozymes A/S
• 12.2 DuPont
• 12.3 dsm-firmenich
• 12.4 Novus International, Inc.
• 12.5 AB Enzymes GmbH
• 12.6 Evonik Industries AG
• 12.7 BASF SE
• 12.8 Amyris, Inc.
• 12.9 Givaudan
• 12.10 Ginkgo Bioworks
• 12.11 Chr. Hansen Holding A/S
• 12.12 Codexis, Inc.
• 12.13 Kerry Group plc
• 12.14 Lonza Group
• 12.15 Corbion N.V.